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ABSTRAK 
Penyakit Von Willebrand's adalah penyakit keturunan yang melibatkan masalah dengan 
pembekuan darah. Penyakit ini didapati sebanyak 1% di dalam populasi keseluruhan. 
Penyakit von Willebrand ini adalah disebabkan kekurangan atau keabnormalan fungsi 
von Willebrand faktor yang akan menyebabkan proses pembekuan darah terganggu. 
Haid berpanjangan dan berlebihan(menoragia) bennaksud pendarahan melebihi 80ml dan 
melebihi 7 hari dan ia merupakan masalah utama perempuan di dalam perigkat umur 
reproduktif. Ia merupakan tanda atau gejala bagi wanita yang mempunyai masalah 
dengan pembekuan darah. Maka, kekerapan penyakit ini serta jenis..jenis vWD ini dikaji 
di kalangan wanita ini. 
Tiga puluh orang wanita yang datang ke klinik sakit p~ HUSM dengan masalah 
pendarahan tanpa keabnormalan pada sistem reproduktif di pilih. Sejarah berkaitan 
dengan masalah pendarahan ditanya dengan terperinci. Ujian Full blood count, 
prothrombin time (PT), activated partial prothrombin time (APIT), ABO blood grouping, 
Faktor VIII (FVIII:C), von Wilebrand faktor antigen (vWF: Ag), von Willebrand faktor 
aktiviti (vWF: Ac) dan collagen binding assay (vWF: CBA) dijalankan. Kemudian ujian 
ristocetin induced platelet aggregation (RIP A) dijalankan kepada mereka yang 
mempunyai keputusan ujian von Willebrand yang abnormal. 
Daripada 30 orang pesakit, 97% adalah Melayu dengan median umur 42 tahun. Empat 
(13.3%) daripada pesakit mempunyai keputusan ujian von Willebrand yang abnormal. 
Dua daripadanya di sahk.an sebagai vWD Type l, seorang sebagai kekurangan von 
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Willebrand berkaitan dengan kumpulan darah 0 dan pesakit yang terahkir disahkan 
menghidap vWD Type 2 samada Type 2A atau 2M. Kajian ini mendapati tiada perkaitan 
di antara umur, pennulaan pendarahan, tempoh pendarahan, sejarah transfusi darah atau 
tanda pendarahan yang lain dengan penyakit von Willebrand. 
Hasil daripada keputusan ujian von Willebrand pada 4 pesakit, functional assay von 
Willebrand (vWF: Ac dan vWF: CBA) mempunyai nilai signifikan yang rendah 
berbanding dengan vWF: Ag dan FVIII:C. Kesan rawatan dengan hormon dan kumpulan 
darah ke atas ujian von Willebrand tidak menunjukkan kesan yang signifkan. 
Kesimpulannya, ini adalah kajian yang pertam.a mengenai penyakit von Willebrand di 
kalangan wanita Malaysia yang mempunyai masalah pendarahan tanpa keabnonnalan 
pada sistem reproductive organ. Insiden penyakit von Wllebrand adalah tinggi. 
Memandangkan ujian sarigan tidak dapat membantu , kami ingin mencadangkan bahawa 




Von Willebrand disease (vWD) is the most common inherited bleeding disorders, found 
in approximately 1% of the general population, without ethnic differences. vWD results 
from a qualitative or quantitative defect in von Willebrand factor (vWF) resulting in 
impaired primary homeostasis. Menorrhagia is defined objectively as > 80ml menstrual 
blood loss per cycle or menses lasting longer than 7 days and is a common gynecologic 
problem in women of reproductive age. However, in 50% of cases, no pathology is 
detectable. Menorrhagia is valuable predictors of bleeding disorder in women. The 
frequency of vWD in women with menorrhagia ranges from 5-50% in different studies. 
The aim of this study is to know the prevalence of vWD in women with menorrhagia of 
unknown cause and identify the subtypes of the disease. 
Thirty women who came to Obstetric and Gynecology Clinic, HUSM with menorrhagia 
without uterine pathology was selected for this study. A detailed history related to 
menorrhagia was acquired from them. Full blood count (FBC), prothrombin time (PT), 
activated partial prothrombin time (APTT), ABO blood grouping, factor VIII activity 
(FVIII: C), von Willebrand factor antigen (vWF: Ag) and von Willebrand factor activity 
(vWF: Ac) and collagen binding assays (vWF: CBA) were measured in all patients. 
Subsequently ristocetin induced platelet aggregation (RIP A) was performed for those 
who had abnormal von Willebrand studies. 
Out of 30, 97% were Malay with median age of 42 years old. Four (13.3%) patients have 
abnormal parameters of von Willebrand studies. Two were diagnosed as 'possible' vWD 
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Type 1, one patient as von Wille brand deficiency related to blood group 0 and the other 
one as 'possible' vWD Type 2 either subtype 2A or 2M. There is no association between 
age, onset of menorrhagia, dtmrtion of menstruation, history of blood transfusion or other 
bleeding tendencies with the development of the disease. 
Based on von Willebrand studies, von Willebrand functional assays (vWF: Ac and vWF: 
CBA) was significantly lower than vWF: Ag and FVIII: C in this 4 patients. Effect of 
hormone replacement therapy and blood group were analyzed and both did not show 
statistically significant in contributing to von Willebrand profiles. 
In conclusion, to date this is the first reported cases of vWD among Malaysian women 
with menorrhagia without uterine pathology. vWD is highly prevalence and though 
coagulation screening test is not helpful, we would like to suggest that a von Willebrand 






1.0 GENERAL INTRODUCTION 
Von Willebrand's disease (vWD) is now recognized to be the most common inherited 
bleeding disorder, found in approximately 1% of general population (Werner et al., 1993). 
Individuals with vWD have defects in, or reduced levels of von Willebrand factor (vWF), 
an adhesive plasma protein essential for primary homeostasis. It is generally an 
autosomal dominant and heterogenous disorder with variable clinical expression as a 
result patients are typed according to pathophysiology. vWD is very heterogenous, and 
may be defined by a reduction or absence of high molecular weight (HMW) vWF, by a 
reduction or absence of all forms of vWF, or by the loss of a specific vWF function 
(Sadler eta/., 2000, 1994; Laffan et al., 2004; Favaloro et al., 2001, 1999). There are 
three major types: Type 1 is due to a partial quantitative deficiency of a normal vWF and 
accounts for 70-80% of all vWD; Type 2 (20% of vWD) includes several qualitative 
defects in vWF and patient with Type 3 vWD (5-10%) is due to complete deficiency of 
vWF and a secondary severe deficiency of FVIII. This condition is associated with 
mucocutaneous bleeding and they may present with echymoses, epistaxis, menorrhagia or 
bleeding following trauma or at the time of surgery. 
The clinical aspects of vWD in females can be pronounced because of the additional 
challenges to the haemostatic system from monthly menstruation and from childbirth. 
Menorrhagia is defined objectively as> 80ml menstrual blood loss (MBL) (Rees eta/., 
1987). Although menorrhagia is a common gynecological symptom, a specific cause is 
identified in less than 50% of affected women. However another 50% of cases, no 
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pathology is detectable and such women are diagnosed as having dysfunctional uterine 
bleeding (DUB) (Rees et al., 1987). 
Recently, there has been growing recognition that vWD is not uncommon in women with 
menorrhagia, with prevalence estimates of 5-20% (Jody et al., 2005), compared with less 
than 1% in women without menorrhagia (Kouides et al., 2002). Despite the high 
prevalence of VWD in the general population, women who are referred for investigation 
of menorrhagia are not routinely screened for this coagulation disorder. 
This study was carried out to assess the frequency of vWD among women presenting 
with menorrhagia in gynecology clinic at Hospital University Sains Malaysia (HUSM). 
We also assessed whether information from the patient's history was a predictive of this 






2.0 LITERATURE REVIEW 
2.1 INTRODUCTION ON VON WILLEBRAND DISEASE 
2.1.1 Defmition 
vWD is a disease of bleeding disorder due to deficiency ofvWF functional activity. The 
abnormality may be quantitative and/or qualitative. 
2.1.2 Background 
vWD is first described by Dr. Erik von Willebrand in 1962 after studying a large family 
Foglo on the island of Aaland in the Gulf of Bothni~ the coast of Sweden. vWD is now 
recognized to be the most common inherited bleeding disorder, manifesting as an 
increased tendency for spontaneous or trauma related bleeding in 1~3% of the general 
population (Murray eta/., 1996). 
2.1.3 Biosynthesis and structure ofvWF 
vWF is a multifunctional plasma protein that plays a prominent role in the events that 
lead to the normal arrest of bleeding. vWF is produced by endothelial cells and either 
stored in intracellular organelles known as Weibel~Palade bodies or secreted 
constitutively by megakaryocytes and stored in platelet alpha-granules (Ruggeri et a/., 
2001 ). The gene coding for vWF is 178 000 bases long, is located on chromosome 12 and 
contains 52 exons. vWF is originated from the vWF precursor (pro·vWF) and 
synthesized as a large precursor protein (360 kD~ 2813 amino acids), which consists of a 
22-amino acid signal peptide, a pro-polypeptide (100 kD~ 741 amino acids) also known 
as vWF antigen II, and a mature subunit (270 kD~ 2050 amino acids). The largest 
proportion of the vWF species is propeptide vWF and in immature form, is secreted 
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through the constitutive pathway. The remainder fully processed and functional vWF is 
stored in the Weibel-Palade bodies and secreted via the regulated pathway. The two 
polypeptides have distinct biological functions. About 1% of plasma vWF contains the 
pro-peptide, possibly due to incomplete processing. Mature vWF both mediates the 
adhesion of blood platelets at sites of vascular injury and functions as a stabilizing carrier 
protein of factor VIII, an essential co-factor in the coagulation system. In addition, vWF 
may help to anchor endothelial cells to the extracellular matrix. The pro-peptide of vWF 
is required for the proper post-translational multimerization and subsequent storage of 
vWF. Dimers are formed in the endoplasmatic reticulum by covalent dimerization of the 
subunits at their C-termini. Multimers are formed in the Golgi apparatus and the secretory 
vesicles by covalent multimerization of these dimers at theN-terminus (Figure 2.1). 
The pro-peptide of vWF is required for normal multimer formation and is cleaved off by 
furin, a dibasic paired amino acid-cleaving enzyme. vWF is released from endothelial 
cells as ultra large multimers and circulates in the plasma as a series of multimers of very 
high molecular weight (500-20 000 kDa). Proteolysis by the specific metalloproteinase, 
ADAMSTl3 is involved in the break down into the smaller multimers, and shear stress 
enhances the susceptibility to proteolytic cleavage. Recently, it was shown that human 
plasma contains a vWF-degrading enzyme, vWF-cleaving protease (vWF-CP) and that 
the cleavage site of this enzyme is located between amino acid residues 842Thr and 
843Met in the A2 domain of the vWF subunit. vWF-CP cleaves ultra large multimers, 
normally stored in Weibel-Palade bodies of vascular endothelium, from which they are 
secreted luminally into plasma and abluminally into the subendothelium. Each vWF 
subunit shows a characteristic pattern of homologous A, B, C and D domains, which are 
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independent building blocks in many other proteins. The pro-peptide contains a D 1 and 
D2 domain. The mature subunit consists ofD'-D3-A1-A2-A3-D4-B1-B2-B3-C1--C2 
domains, and a C-terminal part of 151 amino acids that has no internal homology (Figure 
2.1 ). The average plasma concentration is 10 JLg/mL; the average concentration in 
platelets is 280 ng/1 09 platelets (Rohdeghiero et al., 1992). The normal range of plasma 
vWF, however is broad and strongly influenced by the blood group with 25% lower level 
in blood group 0 and higher level in persons with the AA,BB, or AB loci (Sarode et al., 
2000). The deficiency ofvWF associated with blood Type 0 is not caused by a mutation 
in the vWF gene per se, instead, clearance of vWF protein may be enhanced in people 
with this specific blood type. The mechanism by which this clearance occurs in humans 
is not yet characterized fully (Julie et al., 2001). Platelet vWF is independent of the ABO 
blood type. 
The levels of vWF are variable which are affected by a variety of genetic, physiologic 
and pharmacologic factors including age, blood group and hormonal status. vWF and 
FVIII levels are increased by age, strenuous exercise, inflamrnation(vWF is an acute 
phase reactant), hyperthyroidism and high levels of estrogen during pregnancy or use of 
oral contraceptive. Enhance levels of vWF are associated with a risk for thrombotic 
complications (Philipp et al., 2003). 
The variation in vWF levels during the normal menstrual cycle is not well defined, with 
conflicting results in both longitudinal and cross sectional study (Miller et al., 2002). In 
studies showing a cyclic variation, the lowest vWF and FVIII levels occurred at variable 
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times during the first half of the cycle, with the lowest vWF antigens and activity levels 
during the early follicular phase (day 9 and 1 O)(Kadir et al., 1999). 
2.1.4 Functions of vWF 
After its release from the endothelium and platelets, vWF serves as two essential 
biological functions: mediates the adhesion and aggregation of platelets at sites of 
vascular injury and it modulates the survival and function of factor VIII. In addition, 
proper haemodynamic conditions (a high shear rate) and highly polymerized vWF 
molecules are required to achieve efficient platelet adhesion and aggregation. 
2.1.4.1 Factor VIII binding 
vWF circulates in plasma with factor VIII as a non-covalent complex. These interactions 
extend the survival of factor VIII in the circulation. Any change in plasma vWF level is 
coupled with a concordant change in the plasma concentration of factor VIII. Low v WF 
levels, as in vWD, are also associated with low plasma factor VIII levels. Similarly, 
qualitative vWF defects, as in vWD Type 2N, may abolish proper factor VIII-vWF 
interaction, as a consequence decreasing the plasma factor VIII level. However the 
plasma vWF level is not influenced by the factor VIII level. 
The N terminal D' domain of vWF comprises the primary Factor VIII binding site 
(Lenting et al., 1998). Only in its dimeric form in this Cys-rich domain able to bind factor 
VIII, indicating a complex mode of protein-protein interaction. vWF not only binds to 
factor VIII and thereby controls its biological survival, but also protects factor VIII from 
premature proteolytic cleavages and inactivation. Each vWF monomer is able to bind one 
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factor VIII molecule. In vivo, however, not all vWF monomers are bound to factor VIII. 
Relatively small proportions (1-2%) of the available vWF monomers are occupied by the 
factor VIII (Vlot et al., 1998).These complexes are relatively stable. Upon triggering of 
the coagulation system, one of the vWF-binding sites on the factor VIII molecule is 
cleaved off, notably by thrombin, resulting in the dissociation of the complex and the 
subsequent conversion of factor VIII into its active configuration (factor VIlla) (Saenko 
et al., 1997). 
The vWF modulates the function of factor VIII at various levels. It inhibits the interaction 
between factor VIII and different proteases of the coagulation system, including factor 
IX, Factor X, and protein C, as well as negatively charged phospholipids membranes, 
thereby preventing the premature activation of the coagulation system. These interactions 
are likely to play a significant role in controlling the haemostatic response to vascular 
injury. 
Recent reports have shown that vWF might also control the biological half-life of factor 
VIII by controlling its interaction with low-density lipoprotein receptor-related protein 
(LRP)(Schwarz et a/., 2000). LRP is a multifunctional scavenger receptor involved in the 
clearance of a spectrum of ligands, including proteases, protease-inhibitor complexes, 
lipases and apolipoproteins from the circulation. LRP also binds factor VIII and thereby 
mediates its cellular internalization and degradation. These processes are inhibited by 
vWF. vWF may also control factor VIII clearance by a mechanism independent of the 
premature proteolytic breakdown of factor VIII. 
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2.1.4. 2 Platelet thrombus formation 
At intermediate and higher rates of shear, vWF undergoes a conformational change from 
a closed structure to an extended form that can reach several microns in length and which 
has multiple platelet and collagen binding sites. In this extended form, vWF is able to 
bind platelets through the GPib~IX-V complex and thereby support thrombus formation, 
even at very low rates of shear when immobilized on the surface. This extended form of 
vWF can also be induced using the antibiotic ristocetin or snake venom toxin botrocetin 
(Hoflbrand eta/., 2006). 
vWF's role in this process is dependent on the fast on rate of association to the GPiba 
subunit in the GPib~IX-V complex. The stable recruitment of platelets into the thrombus 
requires interaction with other platelet agonists or very high rates of shear to activate 
platelet integrins. GPib-IX-V binds to a number of other ligands. GPib-IX-V binds to the 
integrin aM~2 on the surface of leucocytes and this interaction along with binding of 
platelet P-selectin to PSGL-1, is implicated in the attachment and transmigration of 
leucocytes through a mural thrombus. GPib-IX-V also binds to P-selectin and this has 
been shown to support rolling of platelets with activated endothelium in low pressure 
vessels. 
Collagen activates platelet via GPVI leading to an increase in affinity of the integrins 
allb~3 and a2~1 for vWF/fibrinogen and collagen respectively. These mediate stable 
adhesion and potentiate activation through further activation of GPVI and also release of 
ADP and TxA2. vWF and fibrinogen, in combination with ADP, TxA2 and thrombin, 
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mediate thrombus formation (aggregation) and stabilization (clot retraction) (Hoftbrand 
et al., 2006). 
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Figure 2.1 Domain structure and processing ofvWF. The domain structure (A-D) of 
prepro vWF and mature are shown (Adapted from Vlot eta/., 1998). 
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2.1.5 Prevalence 
vWD is the most frequent inherited bleeding disorder. Nilsson et a/ (1984), reported a 
frequency of approximately 125 cases per million in Sweden, twice as frequent as for 
haemophilia. Rodeghiero eta, I (1981), during a large Italian epidemiological study in 
children, found the prevalence to be 0.82%. More recent studies in different populations 
among American adults confinn a prevalence of the disease of approximately 1-2% 
(Budde et al., 2001). Among the different vWD types, Type 1 is the most frequent (60--
80%); all Type 2 vWD variants are 15-30%, while Type 3 is diagnosed in 5-10% of 
vWD patients ( Awidi eta/., 1992). 
2.1.5.1 Pathophysiology and classification 
Inherited vWD has been subdivided into three types, which reflect its pathophysiology. 
Type 1 and 3 vWD reflect, respectively, the partial or virtually complete deficiency of 
vWF while Type 2 vWD reflects a qualitative deficiency of vWF. The revised 
classification introduced in 1994 by Sadler et al, recommends that Type 2 vWD is 
subdivided into four subtypes (2A, 2B, 2M, 2N) according to specific details of the 
phenotypic features {Table 2.1 ). 
2.1.6.1 Type 1 
Type 1 is the most frequent form of vWD, inherited as an autosomal dominant trait in 
most cases; recessive transmission of Type 1 v WD defects has also been shown 
(Eikemboom et a/., 1998). Patients with Type 1 vWD are characterized by mild to 
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moderate bleeding symptoms, nonnal or variably prolonged BT and low levels of 
vWF:Ag, vWF:RCo and FVIII and normal multimeric structure. 
Definite diagnosis requires documentation of all three factors: inheritance, a history of 
bleeding, and low levels of nonnal vWF. Limitations of these criteria are the broad 
normal range for vWF levels and the variation of these levels over time (Blomback et al., 
1992). 
Patients with Type 1 vWD are very heterogeneous. Type 1 vWD may be classified in 
three subtypes: Type 1 'platelet normal', with a normal content of functionally normal 
vWF; Type 1 'platelet low', with low concentration of functionally normal vWF; and 
Type 1 'platelet discordanf, with normal concentrations of dysfunctional vWF 
(Mannucci et a/., 1985). Patients with low levels of platelet v WF have more prolonged 
BT and usually more severe symptoms than those with normal platelet vWF, because 
they have also low levels of vWF stored in endothelial cells (Fedrrici et al., 1993). 
The diagnosis of Type 1 vWD may also be complicated by several factors. ABO blood 
groups modify vWF levels in plasma (Gillet al., 1987). A dominant Type 1 vWD has 
been identified with mutated cysteine residues on the 03 domain of vWF (Eikemboom et 
al., 1996). 
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Table 2.1 Classification of vWD 
Type 1 vWD refers to partial quantitative deficiency of vWF 
Type 3 vWD refers to virtually complete deficiency ofvWF 
Type 2 vWD refers to qualitative deficiency ofvWF 
Type 2A refers to qualitative variants with decreased platelet-dependent function that is 
associated with the absence of high-molecular-weight multirners (HMW) 
Type 2B vWD refers to qualitative variants with increased affinity for platelet GPib leading to 
loss ofHMW vWF multimers in plasma. 
Type 2M vWD refers to qualitative variants with decreased platelet-dependent function not 
caused by the absence of HMW vWF multimers 
Type 2N vWD refers to qualitative variants with markedly decreased affinity for factor VIII 
From an updated version by Sadler et al, 1994 
2C 2N 2E 2B 
2M 
2A 
... .(l. 111111 .0. ' 
03 
SP pro--peptide mature VWF subunit 




2.1.6.2.1 Type 2 
In type 2 vWD, there is qualitative abnormality of vWF (Sadler et al., 1994). Patients 
may be having normal levels of vWF protein, but the protein is dysfunctional. These 
variant accounts for 1 5·30% of cases There are four major subtypes with distribution 
estimated as 30% Type 2A, 28% Type 2B, 34% Type 2N, and 8% Type 2M (Sadler et 
a/., 2000). 
Type 2A is the most frequent subtype among Type 2 vWD (Ruggeri et al., 1980). It is 
inherited mainly with an autosomal dominant pattern but a recessive pattern is also 
described (Askura et al., 1997). Patients with Type 2A vWD are identified by normal to 
slightly reduced vWF:Ag levels and markedly low vWF: RCo, with an abnormal 
multimeric pattern characterized by loss of the high molecular weight multimers and 
increase of the intensity of low molecular weight multimers. Type 2A vWD are due to 
specific mutations located within the A2 domain of vWF subunit, and data obtained by 
expression studies show that two mechanisms are responsible for this defect (Meyer et 
a/., 1997)(Figure 2.2). One class of mutations, referred to as group 1, causes defective 
intracellular transport of vWF and impairs the assembly, storage and secretion of large 
vWF multimers in both plasma and platelets. Group 2 mutations do not interfere with 
vWF assembly or secretion, but render the multimers more sensitive to proteolysis in 
plasma (Lyons eta/., 1992). 
Another cause of high molecular weight deficiency in Type 2A vWD is a defective post· 
translational processing that includes defects of dimerization at the vWF C"terminus in 
the subtype previously described as type liD (Enayat et al., 2001 ), and defects of further 
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polymerization of vWF dimers to multimers in their N-termini. The latter multimeriztion 
defects can result either from mutations in the Dl and D2 domains of the vWF 
propeptide, which is necessary to catalyse intermolecular disulphide binding at the D3 
domain of mature vWF in the subtype previously indicated as IIC, or from mutations in 
the D3 domain itself in the subtypes indicated as liE and IIF as well as in Type IIC 
Miami (Schneippenheim eta/., 2001). 
Type 2B can be identified because of heightened response to ristocetin and absence of 
large multimers from plasma (Ruggeri et al., 1980). The multimeric structure of platelet 
vWF and of vWF produced by cultured endothelial cells is normal (De Groot et al., 
1989). The inheritance pattern is mainly autosomal dominant, but cases with apparently 
recessive pattern have also been described (Federici eta/., 1989). 
A large degree of phenotypic heterogeneity has been identified since the original 
description. Typical features for 2B vWD are mild thrombocytopenia with increased 
mean platelet volume, prolonged BT, low to normal FVIII, low to normal vWF:Ag, low 
vWF: RCo and heightened RIPA. Thrombocytopenia can be more pronounced during 
pregnancy (Pareti et al., 1990). In some families, spontaneous platelet aggregation occurs 
(Federici eta/., 1997). More than 20 different missense mutations and one small insertion 
have been identified in Type 2B, all located within the AI domain of the vWF subunit, 
and the abnormal binding to platelet glycoprotein has been confinned by expression 
studies in the majority of these mutants (Meyer et al., 1997)(Figure 2.2). 
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Type 2M ('M' for multimers) includes variants in which binding to platelets is impaired 
but the vWF multimeric distribution is normal. This phenotype may be produced by 
mutations that inactivate specific binding sites for ligand on platelets or collagens. 
Laboratory results generally are similar to those in Type 2A, but there are high molecular 
weight forms. The Type 2M mutations that have been characterized are located within 
domain Al of the vWF subunit and show reduced binding to platelet Gplb in studies of 
expressed mutants (Hillery et al., 1998)(Figure 2.2). Among this subgroup of vWD 
variants, patients with type 2M 'Vicenza' have low levels of vWF antigen but have larger 
than normal multimers (supranonnal) in plasma, similar to those observed in plasma after 
desmopressin infusion and in endothelial cells and platelets (Manucci et a/., 1988). 
Candidate missense mutation in Type 2M 'Vicenza' have been identified in domain 03 
(Schneppenheim eta/., 2000). 
Type 2N vWD ('N' for Normandy) is characterized by normal levels of vWF: Ag and 
vWF:Rco, and normal multimeric structure, but low plasma FVIII levels. It therefore 
resembles haemophilia A, but its inheritance pattern is not X-linked but autosomal 
recessive. Low FVIII levels, at variance with haemophilia, are due to decreased plasma 
half-life of FVIII, which cannot bind to vWF as a consequence of an intrinsic 
abnormality of vWF (Nishino et a/., 1989). Type 2N can be caused by several missense 
mutations, all localized to the D' and D3 domains of vWF subunit (Figure 2.2). Co-
inheritance of a Type 2N mutatiom with a Type 1 vWD allele may contribute to the 
variable expressivity of Type 1 vWD ( Mazurier et al., 1981). 
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2.1.6.3 Type3 
Type 3 (severe) vWD is caused by impaired biosynthesis ofvWF and is characterized by 
undetectable levels of vWF in plasma and platelets. As vWF is also the carrier of FVIII, 
plasma levels of FVTII are very low (1-5%). As a consequence, patients with Type 3 
vWD have a severe bleeding tendency, characterized not only by mucocutaneous 
haemorrhages but also by haemarthroses and haematomas as observed in severe 
haemophilia. The inheritance pattern of Type 3 vWD is autosomal recessive and its 
prevalence is 1-5 per million populations (Sadler eta/., 2000). 
Alloantibodies against vWF may arise in 5-8% of patients treated with FVIII-vWF 
concentrates (Mannuci et al.. 1995); gene deletions predispose to the fonnation of 
alloantibodies (Shelton et al., 1987). The presence of antibodies has been demonstrated in 
vitro by the capacity of patient plasma to inhibit RIP A of normal PRP in a time-
dependent manner (Mannuci et al., 1981). In vivo, the antibodies are responsible for a 
poor clinical response to replacement therapy. In some patients with high antibody titers, 
replacement therapy not only is ineffective but also may trigger life-threatening 
anaphylactic reactions (Mannuchi et al., 1995). The most common mutations in Type 3 
vWD are total or partial deletions, nonsense, splicing and frame shift mutations, found 
throughout the 52 exons of the vWF gene (Zhang eta/., 1995). 
18 
2.1.7 Clinical manifestations 
Patient with vWD may have variable clinical expression. Affected individual may 
experience mucocutaneous such as epistaxis, easy bruising and menorrhagia. Additional 
symptoms include haemorrhage after tooth extraction, haemorrhage after surgery, 
prolonged bleeding after superficial cuts and postpartum haemorrhage. The bleeding 
tendency however is highly variable and depends on the type and severity of the disease. 
In many patients with Type 1 or Type 2 vWD, the bleeding tendency may be mild or 
absent. In contrast with patient Type 3 vWD have a moderately severe haemorrhagic 
tendency; mucosal bleeding is very frequent and may be life-threatening. In addition, due 
to the severe FVIII defect, haematoma and haemarthrosis can occur. 
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2.2 MENORRHAGIA 
Menorrhagia is defmed as menstrual blood loss of 80ml or more per period. It is seen in 
5% of women of reproductive age and 12% of gynecological referrals are because of this. 
Menorrhagia is one of the most common gynecological complaints in contemporary 
gynecology (Warner et al., 2001). Current gynecological surveys report that 30% of all 
premenopausal women perceive menses to be excessive. 
Menorrhagia has been attributed to a number of different general or local causes but in 
more than 50% of cases no organic pathology is found. Increased menstrual blood loss 
has been reported in women with inherited bleeding disorders, especially vWD and 
carriers of hemophilia. Other less common inherited bleeding disorders, including 
deficiencies of prothrombin, fibrinogen, FV, FVII, FX and FXI may also be associated 
with menorrhagia. The frequency of vWD in women with menorrhagia ranges from 5% 
to 20% in different studies {Andra et al., 2004), where as menorrhagia was reported by 
60-95% of women with vWD (Kirtava et al., 2003). Despite this, a recent survey of 
obstetrician-gynecologists found that only 6% believed vWD or other bleeding disorders 
were a frequent cause of menorrhagia (Dilley et al., 2002). 
VWD-associated menorrhagia may be most severe during the first few years after 
menarche (Silwer et al., 1973). In one study of women with objectively confirmed 
menorrhagia, 65% of women with vWD reported an onset at menarche compared to only 
9% of those without a bleeding disorder {Kadir et al., 1991). The frequency ofvWD in 
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adolescents with menorrhagia is not well defined, because most studies evaluating 
prevalence did not include adolescent women (Woo et al., 2002). Several small 
retrospective reviews identified vWD in 2.8-5% of adolescent women requiring urgent 
evaluation or hospitalization for menorrhagia (Bevan et al., 2001). 
The prevalence of menorrhagia in different types of vWD is not well defined. Several 
studies include only one woman with Type 1 disease, 79-93% of whom reported a history 
of excessive menstrual bleeding (Kouides et al., 2000). Severe menorrhagia which 
required blood-product replacement occurred in 86% of women with Type 2 and 3 vWD 
unresponsive to DDA VP (Foster et al., 1995). Other less common inherited bleeding 
disorders, including deficiencies of prothrombin, fibrinogen, FV, FVII, FX, and FIX may 
also be associated with menorrhagia. 
Menstrual blood loss can be assessed by using a special scoring system, a Pictorial Blood 
Assessment Chart (PBAC) (Higham et al., 1990) (APPENDIX 2.) which show a 
reasonable accuracy for assessment menstrual blood loss and diagnosis of menorrhagia 
compared to alkaline haematin method. An accurate prevalence value of menorrhagia in 
vWD appears to be 74% based on a pictorial chart score of over 100 (Kadir et al., 1999). 
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2.3 LABORATORY ASSESSMENT FOR APPROPRIATE DIAGNOSIS AND 
SUBCLASSIFICATION OF VWD 
vWD is heterogenous disorder and patient are type according to pathophysiology. The 
correct diagnosis and sub-classification of patient's vWD is crucial because the 
presenting biological activity of vWF detennined the hemorrhagic risk, and since 
subsequent clinical management will differ accordingly. 
After obtaining a suggestive history and family history, a panel of test must be done to 
diagnose vWD. Many preanalytical variables can cause substantial problems for the 
identification of vWD. The blood is normally collected into a sodium citrate 
anticoagulant tube. Poor collection technique or difficult collection may lead to partial 
sample clotting and loss of high molecular weight of vWF because of entrapment or 
platelet adhesion. The sample transportation and the storage of the samples must be done 
at ambient temperature for a short period ( < 4 hours) as it will not generally affect the 
diagnosis ofvWD. However in contrast, low temperature (refrigerated) transport and /or 
storage will give rise to loss of high molecular weight vWF and misidentification of Type 
1 or Type 2 vWD may occur in normal/non vWD individuals and Type 2 may be 
misdiagnosed in Type 1 vWD individuals. Blood collection in EDTA is more resistant to 
such artifacts, can be used as an alternative specimen for some tests (vWF: Ag, vWF: 
CBA) but not suitable for FVIII:C. Plasma vWF levels also fluctuate in individuals 
according to individual variation (different results are possible on sequential-day 
samples), diurnal variation (levels appear higher later in the day), hormonal influenced ( 
e.g, fluctuations within menstrual cycles, and higher levels in pregnancy. ABO blood 
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group (0-group vWF levels generally lower than non-0 blood group levels), age (levels 
increased with age) and stress. 
In order to diagnose vWD, it is important to detect within the blood of the prospective 
individual, a reduction in level of either the vWF or associated function. Studies requiring 
testing on only one occasion may underestimate the prevalence of vWD due to normal 
fluctuation in vWF levels (Philip et al., 2003). Repeated testing is often necessary to 
confirm or exclude the diagnosis. Because ofvWD heterogeneity, different combinations 
of abnormalities can be determined by the laboratory test panel, and it is the specific 
combination of test results that will help to define the defect. 
Individual laboratory tests differ substantially in their relative power to diagnose vWD or 
to identify its various forms. The laboratory assays used in the diagnosis of vWD can be 
divided by: 
2.3.1 Laboratory screening assays 
2.3.2 Laboratory assay used to confirm and/or classify vWD 
If all the results are normal, and if the initial clinical suspicion was low to begin with 
(presenting history was not striking), no further investigations may be warranted. 
Alternatively, if the history is striking or if results of preliminary testing were abnormal, 
further investigation is warranted and should be specifically tailored to the individual 
being tested. Repeat testing is usually indicated to both exclude a potential testing and 
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collection artifact, and also to confirm findings because of assay variability (Favaloro et 
al., 1999). 
2.3.1 Laboratory screening assays 
Laboratory screening assays is a 'clotting screen', a basic test of coagulation and often 
performed to investigate a case of hypoMcoagulopathy, plateletM:function related disorders 
and vWD or may detect an unsuspected hazard which increases the risk of postoperative 
bleeding. 
2.3.1.1 Routine coagulation tests 
These typically comprise the prothrombin time (PT) and activated partial thromboplastin 
time (APIT). These are standard 'global' clot-based that are usually performed by using 
automated coagulation analyzer with results reported as a clotting times in seconds. 
2.3.1.1.1 Prothrombin time (PT) 
The test measures the clotting time of plasma in the presence of an optimal concentration 
of tissue extract (thromboplastin) and indicates the overall efficiency of the extrinsic 
clotting system. The test is now known to depend also on reactions with factors V ,VII 
and X and on the fibrinogen concentration of the plasma (Quick et al., 1973). This test is 
particularly relevant when patient are being monitored on oral anticoagulant (eg:warfarin) 
therapy, it is not relevant for individuals being assessed for vWD. 
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